EyeArt for diabetic retinopathy screening in Italy: an interview with Dr. Lucio Buratto

In February 2019, EyeArt® AI Eye Screening System was used as part of the Month of Prevention of Diabetic Retinopathy (DR) and Maculopathy that took place throughout Italy. The collaboration between the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk was sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society.

At the end of this month long national screening campaign, EyeArt had helped screen 2434 patients across 25 different centers across Italy using fundus cameras from different manufacturers (CSO, Next Sight, Topcon, Zeiss, and Centervue). Patient reports were available for viewing within 60 seconds of images being submitted. Of the patients screened, 330 patients had referable diabetic retinopathy that had never been diagnosed previously. Nearly 6% of the patients also had clinically significant macular edema (CSME).

“Early detection of DR is an important part of managing care for millions of people with diabetes, yet less than half of the people with diabetes see an eye doctor on an annual basis. AI Eye Screening can make early detection of DR more accessible, allowing patients to seek treatment and likely save their vision,” explained Dr. Lucio Buratto, scientific director of CAMO.

Visit https://www.eyenuk.com for more information about EyeArt® AI Eye Screening System.

#Eyenuk #EyeArt #AIEyeScreening #DiabeticRetinopathy

EyeArt has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada. In the United States, it is limited by federal law to investigational use only.